{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:58:34Z","timestamp":1788026314740,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Natural Science","award":["Grant No.82403717"],"award-info":[{"award-number":["Grant No.82403717"]}]},{"DOI":"10.13039\/501100004761","name":"the Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ6700"],"award-info":[{"award-number":["2024JJ6700"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"China Postdoctoral Science Foundation Funded Project","award":["2024M753696"],"award-info":[{"award-number":["2024M753696"]}]},{"name":"Postdoctoral Innovation Talents Support Program","award":["BX20240431"],"award-info":[{"award-number":["BX20240431"]}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for the Central Universities of Central South University","doi-asserted-by":"crossref","award":["Grant No. 2025ZZTS0258"],"award-info":[{"award-number":["Grant No. 2025ZZTS0258"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10787-025-02086-1","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:55:07Z","timestamp":1765810507000},"page":"797-804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical regions"],"prefix":"10.1007","volume":"34","author":[{"given":"Feng","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaozhi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2086_CR1","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s13555-022-00694-1","volume":"12","author":"A Alexis","year":"2022","unstructured":"Alexis A, de Bruin-Weller M, Weidinger S, Soong W, Barbarot S, Ionita I, Zhang F, Valdez H, Clibborn C, Yin N (2022) Rapidity of improvement in signs\/symptoms of moderate-to-severe atopic dermatitis by body region with abrocitinib in the phase 3 JADE COMPARE study. Dermatol Ther (Heidelb) 12:771\u2013785","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2086_CR2","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","volume":"163","author":"B Chen","year":"2022","unstructured":"Chen B, Zhong J, Li X, Pan F, Ding Y, Zhang Y, Chen H, Liu F, Zhang Z, Zhang L, Drozda R, Oliinyk O, Goh AH, Chen X, Sun X, Rubin DT, Sandborn WJ, Chen M (2022) Efficacy and safety of Ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: a phase ii study. Gastroenterology 163:1555\u20131568","journal-title":"Gastroenterology"},{"key":"2086_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.clindermatol.2018.05.012","volume":"36","author":"R Chopra","year":"2018","unstructured":"Chopra R, Silverberg JI (2018) Assessing the severity of atopic dermatitis in clinical trials and practice. Clin Dermatol 36:606\u2013615","journal-title":"Clin Dermatol"},{"key":"2086_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.pop.2022.12.004","volume":"50","author":"KT Clebak","year":"2023","unstructured":"Clebak KT, Helm L, Uppal P, Davis CR, Helm MF (2023) Atopic dermatitis. Prim Care 50:191\u2013203","journal-title":"Prim Care"},{"key":"2086_CR5","first-page":"590","volume":"101","author":"W Frazier","year":"2020","unstructured":"Frazier W, Bhardwaj N (2020) Atopic dermatitis: diagnosis and treatment. Am Fam Physician 101:590\u2013598","journal-title":"Am Fam Physician"},{"key":"2086_CR6","doi-asserted-by":"publisher","first-page":"11380","DOI":"10.3390\/ijms241411380","volume":"24(14)","author":"JG Gatmaitan","year":"2023","unstructured":"Gatmaitan JG, Lee JH (2023) Challenges and future trends in atopic dermatitis. Int J Mol Sci 24(14):11380","journal-title":"Int J Mol Sci"},{"key":"2086_CR7","doi-asserted-by":"publisher","first-page":"204062232110029","DOI":"10.1177\/20406223211002979","volume":"12","author":"G Girolomoni","year":"2021","unstructured":"Girolomoni G, de Bruin-Weller M, Aoki V, Kabashima K, Deleuran M, Puig L, Bansal A, Rossi AB (2021) Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis 12:20406223211002979","journal-title":"Ther Adv Chronic Dis"},{"key":"2086_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/14712598.2023.2224499","volume":"23","author":"N Gori","year":"2023","unstructured":"Gori N, Ippoliti E, Peris K, Chiricozzi A (2023) Head and neck atopic dermatitis: still a challenging manifestation in the biologic era. Expert Opin Biol Ther 23:575\u2013577","journal-title":"Expert Opin Biol Ther"},{"key":"2086_CR9","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.jaci.2023.07.010","volume":"152","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Irvine AD, Brunner PM, Kim BS, Boguniewicz M, Parmentier J, Platt AM, Kabashima K (2023) The role of Janus kinase signaling in the pathology of atopic dermatitis. J Allergy Clin Immunol 152:1394\u20131404","journal-title":"J Allergy Clin Immunol"},{"key":"2086_CR10","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.2147\/CCID.S439053","volume":"16","author":"T Hagino","year":"2023","unstructured":"Hagino T, Hamada R, Yoshida M, Fujimoto E, Saeki H, Kanda N (2023a) Effectiveness and safety of Upadacitinib in combination with topical corticosteroids in adolescent patients with moderate-to-severe atopic dermatitis. Clin Cosmet Investig Dermatol 16:3201\u20133212","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2086_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1346-8138.16763","volume":"50","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N (2023b) Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol 50:869\u2013879","journal-title":"J Dermatol"},{"key":"2086_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/DER.0000000000000895","volume":"33","author":"JM Hanifin","year":"2022","unstructured":"Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL (2022) The eczema area and severity index-a practical guide. Dermatitis 33:187\u2013192","journal-title":"Dermatitis"},{"key":"2086_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41073-016-0007-6","volume":"1","author":"S Heidari","year":"2016","unstructured":"Heidari S, Babor TF, De Castro P, Tort S, Curno M (2016) Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev 1:2","journal-title":"Res Integr Peer Rev"},{"key":"2086_CR14","doi-asserted-by":"crossref","unstructured":"Jacobson ME, Leshem YA, Apfelbacher C, Spuls PI, Gerbens LAA, Thomas KS, Williams HC, Katoh N, Howells L, Schmitt J, Deckert S, Seshadri R, Simpson EL (2024) Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus Statement. JAMA Dermatol 160:878\u2013886and Harmonising Outcome Measures for Eczema i","DOI":"10.1001\/jamadermatol.2024.1162"},{"key":"2086_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/DER.0000000000000590","volume":"31","author":"J Jaros","year":"2020","unstructured":"Jaros J, Hendricks AJ, Shi VY, Lio PA (2020) A practical approach to recalcitrant face and neck dermatitis in atopic dermatitis. Dermatitis 31:169\u2013177","journal-title":"Dermatitis"},{"key":"2086_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.yapd.2023.03.006","volume":"70","author":"C Kellogg","year":"2023","unstructured":"Kellogg C, Smogorzewski J (2023) Update on atopic dermatitis. Adv Pediatr 70:157\u2013170","journal-title":"Adv Pediatr"},{"key":"2086_CR17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.36849\/JDD.2020.5422","volume":"19","author":"PA Lio","year":"2020","unstructured":"Lio PA, Wollenberg A, Thyssen JP, Pierce EJ, Rueda MJ, DeLozier AM, Ross Terres JA, Anderson P, Milligan G, Piercy J, Silverberg JI, Paul C (2020) Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol 19:943\u2013948","journal-title":"J Drugs Dermatol"},{"key":"2086_CR18","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/pde.13642","volume":"35","author":"M Maarouf","year":"2018","unstructured":"Maarouf M, Saberian C, Lio PA, Shi VY (2018) Head-and-neck dermatitis: diagnostic difficulties and management pearls. Pediatr Dermatol 35:748\u2013753","journal-title":"Pediatr Dermatol"},{"key":"2086_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.det.2024.05.004","volume":"42","author":"K Puerta Durango","year":"2024","unstructured":"Puerta Durango K, Chiesa Fuxench ZC (2024) Global burden of atopic dermatitis: examining disease prevalence across pediatric and adult populations world-wide. Dermatol Clin 42:519\u2013525","journal-title":"Dermatol Clin"},{"key":"2086_CR20","doi-asserted-by":"publisher","first-page":"111029","DOI":"10.1016\/j.intimp.2023.111029","volume":"124","author":"PY Shih","year":"2023","unstructured":"Shih PY, Li CJ, Yong SB (2023) Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment. Int Immunopharmacol 124:111029","journal-title":"Int Immunopharmacol"},{"key":"2086_CR21","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/all.15807","volume":"78","author":"YH Shin","year":"2023","unstructured":"Shin YH, Hwang J, Kwon R, Lee SW, Kim MS, Collaborators GBDAD, Shin JI, Yon DK (2023) Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: a systematic analysis for the global burden of disease study 2019. Allergy 78:2232\u20132254","journal-title":"Allergy"},{"key":"2086_CR22","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s13555-023-00960-w","volume":"13","author":"EC Siegfried","year":"2023","unstructured":"Siegfried EC, Simpson EL, Cork MJ, Arkwright PD, Wine Lee L, Chen Z, Prescilla R, Bansal A, Levit NA, Rodriguez Marco A (2023) Dupilumab treatment leads to rapid and consistent improvement of atopic dermatitis in all anatomical regions in patients aged 6 months to 5 years. Dermatol Ther (Heidelb) 13:1987\u20132000","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2086_CR23","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/jdv.15574","volume":"33","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Chiesa Fuxench ZC, Simpson EL, Gelfand JM (2019) Distribution of atopic dermatitis lesions in united states adults. J Eur Acad Dermatol Venereol 33:1341\u20131348","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2086_CR24","first-page":"10","volume":"241","author":"JP Thyssen","year":"2025","unstructured":"Thyssen JP, Rosmarin D, Costanzo A, Warren R, Chu CY, Chovatiya R, Ladizinski B, Hu X, Liu Y, Calimlim B, Nduaka C, Vigna N, Armstrong A (2025) Efficacy and safety of upadacitinib versus dupilumab treatment for moderate-to-severe atopic dermatitis in four body regions: analysis from the heads up study. Dermatology 241:10\u201318","journal-title":"Dermatology"},{"key":"2086_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.2500\/aap.2022.43.220076","volume":"43","author":"DV Wallace","year":"2022","unstructured":"Wallace DV (2022) Treatment options for moderate to severe atopic dermatitis. Allergy Asthma Proc 43:474\u2013493","journal-title":"Allergy Asthma Proc"},{"key":"2086_CR26","doi-asserted-by":"publisher","first-page":"e15636","DOI":"10.1111\/dth.15636","volume":"35","author":"H Wan","year":"2022","unstructured":"Wan H, Jia H, Xia T, Zhang D (2022) Comparative efficacy and safety of abrocitinib, baricitinib, and Upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther 35:e15636","journal-title":"Dermatol Ther"},{"key":"2086_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/1346-8138.14116","volume":"45","author":"W Wei","year":"2018","unstructured":"Wei W, Anderson P, Gadkari A, Blackburn S, Moon R, Piercy J, Shinde S, Gomez J, Ghorayeb E (2018) Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol 45:150\u2013157","journal-title":"J Dermatol"},{"key":"2086_CR28","first-page":"224","volume":"120","author":"A Wollenberg","year":"2023","unstructured":"Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S (2023) Atopic dermatitis in children and adults-diagnosis and treatment. Dtsch Arztebl Int 120:224\u2013234","journal-title":"Dtsch Arztebl Int"},{"key":"2086_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jdv.19426","volume":"38","author":"S Yoon","year":"2024","unstructured":"Yoon S, Kim K, Shin K, Kim HS, Kim B, Kim MB, Ko HC, Kim YH (2024) The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 38:52\u201361","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2086_CR31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40257-021-00627-2","volume":"22","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zhang L, Ding Y, Tao X, Ji C, Dong X, Lu J, Wu L, Wang R, Lu Q, Goh AH, Liu R, Zhang Z, Zhang J (2021) Efficacy and safety of SHR0302, a highly selective Janus kinase 1 Inhibitor, in patients with moderate to severe atopic dermatitis: a phase II randomized clinical trial. Am J Clin Dermatol 22:877\u2013889","journal-title":"Am J Clin Dermatol"},{"key":"2086_CR30","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jamadermatol.2025.0982","volume":"161","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Gooderham M, Yang B, Wu J, Wu L, Loo WJ, Toth D, Sauder M, Li J, Chen A, Tao X, Lu J, Song Z, Han J, Li H, Li Y, Xu L, Zhang J (2025) Ivarmacitinib for moderate to severe atopic dermatitis in adults and adolescents: a phase 3 randomized clinical trial. JAMA Dermatol 161:688\u2013697","journal-title":"JAMA Dermatol"},{"key":"2086_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","volume":"89","author":"C Zhou","year":"2023","unstructured":"Zhou C, Yang X, Yang B, Yan G, Dong X, Ding Y, Fan W, Li L, Yang D, Fang H, Ji C, Cheng H, Zhang S, Goh AH, Liu R, Gu X, Weng Z, Foley P, Sinclair R, Zhang J (2023) A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of Ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata. J Am Acad Dermatol 89:911\u2013919","journal-title":"J Am Acad Dermatol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02086-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-02086-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02086-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:27:22Z","timestamp":1769704042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-02086-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2086"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-02086-1","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethical committees at each site approved the protocols.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each patient gave written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}